Ivosidenib
Tibsovo
Near Add Your Location
Accepting patients
PyramIDH
A Phase 3, Multicenter, Open Label, Randomized, Non-comparative Two-arm Study of Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Adult Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an Isocitrate Dehydrogenase-1 (IDH1) Mutation (PyramIDH Study)
- IDH1 Inhibitor
- Randomization
- Phase 3
Accepting patients
CPX-351 Plus Ivosidenib
Phase II Investigator Sponsored Study of CPX-351 in Combination With Ivosidenib for Patients With IDH1 Mutated Acute Myeloid Leukemia or High-Risk MDS
- IDH1 Inhibitor
- Phase 2
Accepting patients
Ivosidenib (AG120)
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
- BCL-2 Inhibitor
- Hypomethylating Agents (HMA)
- IDH1 Inhibitor
- Phase 1/2
- Has results
Accepting patients
AG-120
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- IDH1 Inhibitor
- Phase 1
Showing 1-4 of 4